Chordia Therapeutics Faces Fiscal Year Losses

Chordia Therapeutics Inc. (JP:190A) has released an update.

Chordia Therapeutics Inc. reported a challenging fiscal year ending August 2024, with net losses across the board and a basic earnings per share drop to -31.11 yen. The company’s total assets decreased from the previous year, while its equity ratio slightly fell from 91.2% to 89.8%. Despite negative cash flows from operating activities, Chordia Therapeutics maintains a positive cash and cash equivalents balance of 4,329 million yen.

For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.